Empliciti revenue trends

In 2016, Bristol-Myers Squibb’s (BMY) Empliciti reported revenues of ~$133 million. The US accounted for ~89% of Empliciti’s total revenues. In 1Q17, Empliciti generated revenues of ~$53 million, which represents a ~89% YoY (year-over-year) rise and a 13% sequential rise. The drug’s sales in the US totaled ~$36 million.

In November 2015, the FDA (US Food and Drug Administration) approved Empliciti in combination with Revlimid and dexamethasone for the treatment of MM (multiple myeloma) patients who have received one to three prior therapies. Since its approval in November 2015, the drug has witnessed a double-digit growth rate sequentially.

Why Bristol-Myers Squibb’s Empliciti Matters in 2017

About Empliciti

Empliciti (elotuzumab) is an SLAMF7-directed immunostimulatory monoclonal antibody indicated for the treatment of patients with MM who have received one to three previous therapies. Empliciti is administered in combination with lenalidomide (Revlimid) and dexamethasone. The drug activates natural killer cells to combat MM.

In June 2017, BMY presented the four-year follow-up data from its Eloquent-2 phase-3 trial, which evaluated the efficacy of Empliciti in combination with lenalidomide-dexamethasone, compared with lenalidomide-dexamethasone alone. After four years, Empliciti and lenalidomide-dexamethasone combination therapy demonstrated a continued reduction with the risk of disease progression or death of 29%.

The study demonstrated a sustained improvement of 50% with a PFS (progression-free survival) rate of 21% in patients receiving combination therapy, compared with 14% in patients receiving lenalidomide therapy alone. The study also demonstrated an ORR (overall response rate) of 79%, or 235 of 321 patients, compared with 66%, or 214 of 325 of patients, receiving lenalidomide alone. The data proves the efficacy of Empliciti over the long-term.

Still, BMY’s Empliciti faces stiff competition from Celgene’s (CELG) Pomalyst, Amgen’s (AMGN) Kyprolis, and Johnson & Johnson’s (JNJ) Darzalex. The Vanguard Health Care ETF (VHT) has ~2.7% of its total portfolio holdings in BMY.

Latest articles

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.

Square (SQ) was absent from the list of the inaugural members of the Libra Association, the entity that will ensure that Facebook’s (FB) Libra cryptocurrency works as intended. Nearly 30 companies have joined the Libra Association.

Kroger (KR) stock fell 2.2% on June 20—the day the company announced its results for the first quarter, which ended on May 25. The negative sentiment for the stock continued.